Navigation Links
Reportlinker Adds Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs
Date:12/8/2010

NEW YORK, Dec. 8, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs

http://www.reportlinker.com/p0336653/Diabetes-Market-to-2016---Biguanides-and-Insulin-Analogs-will-be-the-Largest-Selling-Anti-Diabetic-Drugs.html

Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs

SummaryGBI Research's new report, "Diabetes Market to 2016 - Biguanides and Insulin Analogs to be the Largest Selling Anti-Diabetic Drugs", provides in-depth analysis of unmet needs, drivers and barriers that impact the global diabetes therapeutics market.. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The scope of this report includes:

- Annualized market data for the diabetes therapeutics market from 2001 to 2009, forecast forward to 2016.

- Market characterization of the diabetes therapeutics market, including market size, annual cost of therapy and treatment usage patterns.

- Key drivers and barriers that have a significant impact on the market.

- Coverage of pipeline molecules in various phases of drug development. .

- Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global diabetes therapeutics market.

Reasons to buyThe report will enhance your decision making capability. It will allow you to

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.

- Develop key strategic initiatives by understanding the key focus areas of leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

1 Table of Contents 3

1.1 List of Tables 6

1.2 List of Figures 8

2 Global Diabetes Market: Introduction 10

2.1 GBI Research Report Guidance 10

3 Global Diabetes Market: Market Overview 11

3.1 Introduction 11

3.2 Unmet Needs 11

3.2.1 Heart Risks Associated with some of the Oral Anti-diabetic Drugs 11

3.2.2 Carcinogenic Effects Associated With Insulin Analogs 12

3.2.3 Poor Patient Compliance 12

3.3 Revenue 12

3.4 Annual Cost of Therapy 14

3.5 Treatment Usage Patterns 15

3.5.1 Diseased Population 17

3.5.2 Treatment Seeking Population 18

3.5.3 Diagnosed Population 19

3.5.4 Prescription Population 20

3.6 Drivers and Restraints of Diabetes Market 21

3.6.1 Drivers of Diabetes Market 21

3.6.2 Restraints of Diabetes Market 21

4 Global Diabetes Market: Geographical Landscape 23

4.1 The US 25

4.1.1 Revenue 25

4.1.2 Annual Cost of Therapy 27

4.1.3 Treatment Usage Patterns 28

4.2 Top Five EU Countries 33

4.2.1 Revenue 33

4.2.2 Annual Cost of Therapy 35

4.2.3 Treatment Usage Patterns 36

4.3 Japan 41

4.3.1 Revenue 41

4.3.2 Annual Cost Therapy 42

4.3.3 Treatment Usage Patterns 43

5 Global Diabetes Market: Therapeutic Landscape 48

5.1 Type 1 Diabetes Market 48

5.1.1 Introduction 48

5.1.2 Symptoms 48

5.1.3 Treatment 48

5.1.4 Unmet need 50

5.1.5 Revenue 51

5.1.6 Annual Cost of therapy 52

5.1.7 Treatment Usage Patterns 54

5.1.8 Drivers and Restraints for the Type 1 Diabetes Market 60

5.2 Type 2 diabetes Therapeutics Market 61

5.2.1 Introduction 61

5.2.2 Symptoms 61

5.2.3 Treatment 62

5.2.4 Unmet need 62

5.2.5 Revenue 63

5.2.6 Annual Cost of therapy 64

5.2.7 Treatment Usage Patterns 66

5.2.8 Drivers and Restraints for the Type 2 Diabetes Market 72

5.3 Revenues by Class of Drugs of Type 2 Diabetes 74

6 Global Diabetes Market: Pipeline Analysis 77

6.1 Introduction 77

6.1.1 Research and Development Pipeline – Type 1 Diabetes 79

6.1.2 Research and Development Pipeline – Type 2 Diabetes 83

6.2 Innovations in Diabetes Treatment 94

6.2.1 Insulin in Pills (Oral Delivery) 94

6.2.2 Promising Treatments for Diabetic Retinopathy 94

6.2.3 Biomarkers in Diabetes 94

6.2.4 Combination Drugs are an Important Part of the Diabetes Therapeutics Pipeline 94

6.3 Drug Delivery in Diabetes 95

6.3.1 Factors Determining Preference for Drug Delivery 95

6.3.2 Desirable Drug Delivery Methods for Diabetes are Currently Unavailable 95

6.3.3 Innovation in Drug Delivery Systems 96

6.4 Profiles of Promising Drugs in the Diabetes Market 97

6.4.1 rhGAD65 (Diamyd) 97

6.4.2 DiaPep277 97

6.4.3 Otelixizumab 98

6.4.4 Oral-lyn 99

6.4.5 BMS-512148 (dapagliflozin) 100

6.4.6 Victoza (liraglutide) 101

6.4.7 D-Tagatose 103

6.4.8 JNJ-28431754 (canagliflozin) 103

6.4.9 MB07803 104

7 Global Diabetes Market: Competitive Landscape 106

7.1 Diabetes Market Overview 106

7.1.1 Human Insulin Products and Oral Anti-diabetic Drugs Like Actos Group (Actos and Actoplus met) and Lantus Have Led Market Growth 106

7.2 Market Share Analysis: Diabetes 107

7.3 Competitive Profiling 108

7.3.1 Novo Nordisk 109

7.3.2 Sanofi-Aventis 116

7.3.3 Takeda 121

7.3.4 Eli Lilly 124

7.3.5 GlaxoSmithKline (GSK) 130

7.3.6 Merck & Co Inc 134

7.3.7 Amylin Pharmaceuticals 137

8 Global Diabetes Market: M&A Landscape 141

8.1 Overview 141

8.1.1 M&A by Geography 142

8.1.2 M&A by Value ($) 143

8.2 R&D Licensing Agreements 143

8.2.1 Deals by Geography 145

8.2.2 Deals by Value ($) 146

9 Global Diabetes Market: Appendix 147

9.1 Market Definitions 147

9.2 Abbreviations 147

9.3 Research Methodology 149

9.3.1 Coverage 149

9.3.2 Secondary Research 149

9.3.3 Primary Research 149

9.3.4 Forecasts 150

9.3.5 Expert Panel Validation 152

9.4 Contact Us 153

9.5 Disclaimer 153

9.6 Sources 1531.1 List of Tables

Table 1: Diabetes Therapeutics Market, Global, Revenue ($bn), 2001-2009 13

Table 2: Diabetes Therapeutics Market, Global, Revenue ($bn), 2009-2016 13

Table 3: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 15

Table 4: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016 15

Table 5: Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009 16

Table 6: Diabetes Therapeutics Market, Global, Treatment Usage Patterns(millions), 2009-2016 16

Table 7: Diabetes Market, Global, Revenue Analysis by Geography ($bn), 2001-2009 23

Table 8: Diabetes Market, Global, Revenue Analysis by Geography ($bn), 2009-2016 24

Table 9: Diabetes Market, The US, Revenues ($bn), 2001-2009 26

Table 10: Diabetes Therapeutics Market, The US, Revenues ($bn), 2009-2016 26

Table 11: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2001-2009 27

Table 12: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2009-2016 27

Table 13: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (millions), 2001-2009 28

Table 14: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (millions), 2009-2016 29

Table 15: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenues ($bn), 2001-2009 34

Table 16: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenues ($bn), 2009-2016 34

Table 17: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2001-2009 35

Table 18: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2009-2016 35

Table 19: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2001-2009 36

Table 20: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2009-2016 37

Table 21: Diabetes Therapeutics Market, Japan, Revenue ($bn), 2001-2009 41

Table 22: Diabetes Therapeutics Market, Japan, Revenue ($bn), 2009-2016 41

Table 23: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2009 42

Table 24: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009-2016 42

Table 25: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2001-2009 43

Table 26: Diabetes Market, Japan, Treatment Usage Patterns(millions), 2009-2016 44

Table 27: Type 1 Diabetes Therapeutics Market, Types of Insulin Regimen 49

Table 28: Type 1 Diabetes Therapeutics Market, Global, Revenue ($bn), 2001-2009 51

Table 29: Type 1 Diabetes Therapeutics Market, Global, Revenue ($bn), 2009-2016 51

Table 30: Type 1 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 53

Table 31: Type 1 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016 53

Table 32: Type 1 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009 55

Table 33: Type 1 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2009-2016 55

Table 34: Type 2 Diabetes Therapeutics Market, Global, Revenue ($bn), 2001-2009 64

Table 35: Type 2 Diabetes Therapeutics Market, Global, Revenue ($bn), 2009-2016 64

Table 36: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 65

Table 37: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016 65

Table 38: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009 67

Table 39: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2009-2016 67

Table 40: Type 2 Diabetes Therapeutics Market, Global, Revenues By Class of Drugs ($bn), 2001-2009 75

Table 41: Type 2 Diabetes Therapeutics Market, Global, Revenues By Class of Drugs ($bn), 2009-2016 76

Table 42: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase III, 2010 80

Table 43: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase II, 2010 81

Table 44: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase I, 2010 82

Table 45: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Preclinical, 2010 82

Table 46: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase III, 2010 84

Table 47: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase II, 2010 86

Table 48: Diabetes Market, Global, R&D Pipeline by Phase in Type 2 Diabetes Market, Phase I, 2010 89

Table 49: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Preclinical, 2010 92

Table 50: Diabetes Therapeutics Markets, Factors Determining Preference of Drug Delivery in Diabetes, 2010 95

Table 51: Desirable Drug Delivery Methods for Diabetes are Currently Unavailable, 2010 95

Table 52: Diabetes Therapeutics Market, Novo Nordisk, Pipeline Products, 2010 114

Table 53: Diabetes Therapeutics Market, Sanofi-Aventis, Pipeline Products, 2010 120

Table 54: Diabetes Market, Takeda, Pipeline Products, 2010 123

Table 55: Diabetes Therapeutics Market, Eli Lilly, Pipeline Products, 2010 128

Table 56: Diabetes Therapeutics Market, GSK, Pipeline Products, 2010 133

Table 57: Diabetes Therapeutics Market, Merck, Pipeline Products, 2010 136

Table 58: Diabetes Therapeutics Market, Amylin, Pipeline Products, 2010 1391.2

List of FiguresFigure 1: Diabetes Therapeutics Market, Global, Revenue($m), 2001-2016 13

Figure 2: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 14

Figure 3: Diabetes Therapeutics Market, Global, Treatment Usage Patterns ('000), 2001-2016 15

Figure 4: Diabetes Therapeutics Market, Global, Diseased Population ('000), 2001-2016 17

Figure 5: Diabetes Therapeutics Market, Global, Treatment Seeking Population ('000), 2001-2016 18

Figure 6: Diabetes Therapeutics Market, Global, Diagnosis Population ('000), 2001-2016 19

Figure 7: Diabetes Therapeutics Market, Global, Prescription Population ('000), 2001-2016 20

Figure 8: Diabetes Market, Global, Revenue Analysis by Geography ($bn), 2001-2016 23

Figure 9: Diabetes Therapeutics Market, The US, Revenue ($m), 2001-2016 25

Figure 10: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2001-2016 27

Figure 11: Diabetes Therapeutics Market, The US, Treatment Usage Patterns ('000), 2001-2016 28

Figure 12: Diabetes Therapeutics Market, the US, Diseased Population ('000), 2001-2016 29

Figure 13: Diabetes Therapeutics Market, the US, Treatment Seeking Population ('000), 2001-2016 30

Figure 14: Diabetes Therapeutics Market, The US, Diagnosis Population ('000), 2001-2016 31

Figure 15: Diabetes Therapeutics Market, The US, Prescription Population ('000), 2001-2016 32

Figure 16: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenue ($m), 2001-2016 34

Figure 17: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2001-2016 35

Figure 18: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns ('000), 2001-2016 36

Figure 19: Diabetes Therapeutics Market, Top Five Countries of Europe, Diseased Population ('000), 2001-2016 37

Figure 20: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Seeking Population ('000), 2001-2016 38

Figure 21: Diabetes Therapeutics Market, Top Five Countries of Europe, Diagnosis Population ('000), 2001-2016 39

Figure 22: Diabetes Therapeutics Market, Top Five Countries of Europe, Prescription Population ('000), 2001-2016 40

Figure 23: Diabetes Therapeutics Market, Japan, Revenue ($m), 2001-2016 41

Figure 24: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2016 42

Figure 25: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2001-2016 43

Figure 26: Diabetes Therapeutics Market, Japan, Diseased Population ('000), 2001-2016 44

Figure 27: Diabetes Therapeutics Market, Japan, Treatment Seeking Population ('000), 2001-2016 45

Figure 28: Diabetes Therapeutics Market, Japan, Diagnosis Population ('000), 2001-2016 46

Figure 29: Diabetes Therapeutics Market, Japan, Prescription Population ('000), 2001-2016 47

Figure 30: Type 1 Diabetes Therapeutics Market, Global, Unmet Need, 2010 50

Figure 31: Type 1 Diabetes Therapeutics Market, Global, Revenue ($m), 2001-2016 51

Figure 32: Type 1 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 52

Figure 33: Type 1 Diabetes Therapeutics Market, Global, Treatment Usage Patterns ('000), 2001-2016 54

Figure 34: Type 1 Diabetes Therapeutics Market, Global, Diseased Population ('000), 2001-2016 56

Figure 35: Type 1 Diabetes Therapeutics Market, Global, Treatment Seeking Population ('000), 2001-2016 57

Figure 36: Type 1 Diabetes Therapeutics Market, Global, Diagnosis Population ('000), 2001-2016 58

Figure 37: Type 1 Diabetes Therapeutics Market, Global, Prescription Population ('000), 2001-2016 59

Figure 38: Type 1 Diabetes Therapeutics Market, Global, Drivers and Restraints, 2009 61

Figure 39: Type 2 Diabetes Therapeutics Market, Global, Unmet Need, 2010 62

Figure 40: Type 2 Diabetes Therapeutics Market, Global, Revenues ($m), 2001-2016 63

Figure 41: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 64

Figure 42: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns ('000), 2001-2016 66

Figure 43: Type 2 Diabetes Therapeutics Market, Global, Diseased Population ('000), 2001-2016 68

Figure 44: Type 2 Diabetes Therapeutics Market, Global, Treatment Seeking Population ('000), 2001-2016 69

Figure 45: Type 2 Diabetes Therapeutics Market, Global, Diagnosis Population ('000), 2001-2016 70

Figure 46: Type 2 Diabetes Therapeutics Market, Global, Prescription Population ('000), 2001-2016 71

Figure 47: Type 2 Diabetes Therapeutics Market , Global, Market Drivers and Barriers, 2009-2016 73

Figure 48: Type 2 Diabetes Therapeutics Market , Global, Market Share by Class of Drugs, 2009-2016 74

Figure 49: Type 2 Diabetes Therapeutics Market, Global, Revenues By Class of Drugs ($bn), 2001-2009 75

Figure 50: Type 2 Diabetes Therapeutics Market, Global, Revenues By Class of Drugs ($bn), 2009-2016 76

Figure 51: Diabetes Therapeutics Market, Global, R&D Pipeline by Indication (%), 2010 77

Figure 52: Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 78

Figure 53: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 79

Figure 54: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 83

Figure 55: Diabetes Therapeutics Market, Global, Share of Top Manufacturers (%), 2010 107

Figure 56: Diabetes Therapeutics Market, Global, Revenue of Top Seven Players ($m), 2007-2009 108

Figure 57: Diabetes Therapeutics Market, Novo Nordisk, Revenue Segments (%), 2009 110

Figure 58: Diabetes Therapeutics Market, Novo Nordisk, Revenue by Product (%), 2009 111

Figure 59: Diabetes Therapeutics Market, Novo Nordisk, SWOT Analysis, 2010 115

Figure 60: Diabetes Therapeutics Market, Sanofi-Aventis, Revenue Segment (%), 2009 116

Figure 61: Diabetes Therapeutics Market, Sanofi-Aventis, Diabetes Revenue by Product (%), 2009 117

Figure 62: Diabetes Therapeutics Market, Sanofi-Aventis, SWOT Analysis, 2010 120

Figure 63: Diabetes Therapeutics Market, Takeda, Revenue Segments (%), 2009 121

Figure 64: Diabetes Therapeutics Market, SWOT Analysis, Takeda, 2010 123

Figure 65: Diabetes Therapeutics Market, Eli Lilly, Revenue Segments (%), 2009 124

Figure 66: Diabetes Therapeutics Market, Eli Lilly, Diabetes Revenue by Product (%), 2009 125

Figure 67: Diabetes Therapeutics Market, SWOT Analysis, Eli Lilly, 2010 129

Figure 68: Diabetes Therapeutics Market , GSK, Revenue Segments (%), 2009 130

Figure 69: Therapeutics Market, GSK, Diabetes Revenue by Product (%), 2009 131

Figure 70: Diabetes Therapeutics Market, GSK, SWOT Analysis, 2010 133

Figure 71: Diabetes Therapeutics Market, Merck, Diabetes Revenue as Percentage of Total Revenue (%), 2009 134

Figure 72: Diabetes Therapeutics Market, Merck, SWOT Analysis, 2010 136

Figure 73: Diabetes Therapeutics Market, Amylin, Diabetes Revenue as Percentage of Total Revenue (%), 2009 137

Figure 74: Diabetes Therapeutics Market, Amylin, Diabetes Revenue by Product (%), 2009 138

Figure 75: Diabetes Therapeutics Market, Amylin, SWOT Analysis, 2010 140

Figure 76: Diabetes Therapeutics Market, Global, Major M&As By Geography (%), n=48, 2009-2010 142

Figure 77: Diabetes Therapeutics Market, Global, Major M&As By Value ($), n=48, 2009-2010 143

Figure 78: Diabetes Therapeutics Market, Global, Major Licensing Agreements By Geography ($), n=76, 2009-2010 145

Figure 79: Diabetes Therapeutics Market, Global, Major Licensing Agreement By Value ($), n=76, 2009-2010 146

Figure 80: GBI Research Market Forecasting Model 152

Companies mentioned To order this report:Pathology Industry: Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Contact:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
Breaking Medicine Technology:
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
(Date:6/24/2016)... ... ... recruitment firm Slone Partners is pleased to announce the placement of Suzanne ... of North American Capital Sales at HTG Molecular . , In ... commercialization of the HTG EdgeSeq system and associated reagents in North America. , Headquartered ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider ... and other difficult to transfect cells, announces its launch of the PluriQ™ G9™ ... Editing System is a complete system for culturing and transfecting human pluripotent ...
Breaking Medicine News(10 mins):